Artax Biopharma

All Events Fund articles Fund PR Portfolio articles Portfolio PR

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma to present Phase 2a data on Nck modulatorAX-158, establishing novel mechanism of action in autoimmune disease at the 2025 SID Annual Meeting

2025.04.252025.04.30 / Late breaker abstract presentation to showcase clinical validation of first-in-class oral small molecule AX-158 in cohort of patients with psoriasis Full dataset to expand on previously announced ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma presents new preclinical data on Nck modulators at 2025 AAD Annual Meeting

2025.03.102025.04.30 / Nck modulator reduced evidence of inflammation in an animal model of dermal irritation Compelling preclinical data support continued development of Nck modulators in atopic dermatitis Cambridge ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma to present on first-in-class Nck modulator at the 2025 AAD Annual Meeting

2025.03.032025.04.30 / Poster presentation on evaluation of Nck modulator in atopic dermatitis models Cambridge, MA, March 3, 2025 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on tran ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study

2025.01.222025.04.30 / Novel breakthrough: first molecule to modulate the fundamental mechanism ofT cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158

2024.08.132025.04.30 / AX-158 has broad potential to treat many autoimmune diseases without causing immunosuppression Psoriasis biomarker panel and PASI scores expected later this year Cambridge, MA, August 13, 2024 ...

Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158.

2024.02.132024.05.13 / Safety and Efficacy Results Are Expected in Second Half of 2024 Evaluating AX-158, a First in Class Nck Blocker, Shifting the Paradigm of Autoimmune Disease Treatment. AX-158 Has Broad Poten ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study

2024.01.092024.05.13 / Patient Enrollment Expected to Begin by Year End Phase 2a Study Seeks to Demonstrate the Safety and Efficacy of AX-158 in Patients with Mild-to-Moderate Psoriasis, Further Advancing a New Approach ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Announces Executive Team Changes, Expansion as Company Heads into Pivotal 2024 Year

2024.01.042024.05.13 / Former Board Chair Dr. Rob Armstrong Now Artax CEO as Joseph Lobacki Moves to Advisory Role Additional Promotions Include Dr. Andre Hoekema to Board Chair, Dr. Maria Nichol to Chief Business Offic ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases

2023.06.022024.05.13 / Phase 1 Findings Demonstrated that Investigational Agent AX-158 Was Well Tolerated at All Doses, with a Profile that Strongly Supports Further Clinical Development Efforts AX-158 is Being Develope ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

A patient-centric mission for life-changing autoimmune treatments

2023.02.232024.05.13 / Artax Biopharma is committed to radical innovation. But for the US-based biotech company and CEO Joseph Lobacki, the only innovations that truly matter are the ones that make a meaningful differe ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma Expands Company’s Scientific Advisory Board and Welcomes James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D., Both Experts in T-Cell-Mediated Diseases

2022.11.162024.05.13 / Cambridge, MA, November 15, 2022 Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T-cell-mediated diseases, today announces the Company is str ...

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases

2022.05.112024.05.13 / Close of $26 Million Funds Immunomodulation Candidate AX-158 DevelopmentAdds New Investors Eli Lilly and Company and Sound Bioventures Cambridge, MA, May 11, 2022 - Artax Biopharma, Inc., a clinic ...